Abstract: The present disclosure provides a liquid composition comprising posaconazole, and a preparation method and use thereof. The liquid composition comprises posaconazole, a cyclodextrin, a dilution stabilizer, an antioxidant, and an acidic pH regulator. The dilution stabilizer comprises hydroxypropyl cellulose and/or hydroxypropyl methylcellulose, and the cyclodextrin is present in an amount of 25% to 45% (w/v), based on the total volume of the liquid composition. The liquid composition can increase an oral bioavailability of posaconazole, mitigate an impact of food on bioavailability of posaconazole, and improve patient compliance.

Abstract: The present disclosure provides a pharmaceutical composition comprising isavuconazole, a first nonionic surfactant, a stabilizer, a degradation inhibitor, and a diluent, wherein the first nonionic surfactant comprises copovidone and poloxamer, a method for preparing the pharmaceutical composition, and a method for treating, ameliorating or preventing related diseases by administering the pharmaceutical composition.

Abstract: The present disclosure relates to an in situ ready-to-use injection formulation of posaconazole free of cyclodextrin and derivatives of cyclodextrin, which can be formulated in situ as a nanosuspension injection of posaconazole by a simple dilution operation during clinical use. The formulation has no adverse effects on the renal function of patients, no extreme pH, and low vascular irritation, and can be administrated without the need for central venous cannulation during clinical use. The present disclosure also relates to a method for preparing the formulation and the use of the formulation in the treatment and prevention of fungal infections.

Abstract: The present disclosure provides an antifungal drug inhalation formulation, comprising: crystalline nanoparticles of a triazole antifungal drug. The present disclosure further provides a preparation method and use of the antifungal drug inhalation formulation.

Abstract: Provided are a pharmaceutical composition for topical administration for the treatment of eye diseases and ear diseases caused by fungal infections, such as fungal keratitis, otitis externa or otitis media caused by fungal infections, and a preparation method thereof. The pharmaceutical composition comprises a triazole antifungal agent as an active ingredient, a non-aqueous solvent, and optionally a tonicity regulator, and may be a non-aqueous preservative-free composition. The non-aqueous composition of the present disclosure has one or more of the following advantages: high stability, preservative-free, low irritation, increased concentration of the antifungal agent in local tissues, reduced systemic toxicity and side effects, increased retention time of the antifungal agent in local tissues, reduced administration frequency, and improved patient compliance.

Abstract: The present disclosure provides a pharmaceutical formulation, wherein raw materials for formulating the pharmaceutical formulation comprise: an active ingredient which is one selected from the group consisting of peramivir, zanamivir, laninamivir, and hydrates or solvates thereof; a carboxylic acid anion donor which is at least one selected from the group consisting of pamoic acid and hydroxynaphthoic acid; and a first pH regulator which is an alkaline pH regulator.

Abstract: The present application discloses an intestine-targeted drug delivery composition, comprising in sequence, from inside to outside, (1) a microsphere core and a pH-independent sustained-release layer containing an active ingredient, or a microsphere containing an active ingredient and a pH-independent sustained-release layer, or a microsphere containing an active ingredient and a pH-independent sustained-release material, (2) a pH-dependent coating layer, and (3) a time-dependent pulsatile controlled-release layer. The intestine-targeted drug delivery composition of the present application delivers the active ingredient to intestinal tissues (especially colon tissue) for release, reduces the systemic blood concentration of the active ingredient, and improves the pharmacokinetic characteristics and concentration of the active ingredient in intestinal tissues. The composition is suitable for treating intestinal diseases, such as inflammatory bowel diseases including Crohn's disease and ulcerative colitis.